Clik here to view.
Mark Pruzanski gets another shot at MASH, joining as chair of Inventiva as it...
After flashing warning signs in July with only enough money for that month, Inventiva has now secured a lifeline to keep its Phase 3 liver disease study afloat. The French biotech said Monday it got...
View ArticleNovartis ends mid-stage IPF trial, will keep testing drug in PAH
Novartis has terminated a mid-stage trial of an oral treatment candidate for idiopathic pulmonary fibrosis, the company confirmed to Endpoints News. The Swiss pharma giant axed a Phase 2 study of...
View ArticleEndpoints AI coverage: Come hear from two Nobel winners at our events
More than a year ago, Endpoints News made the decision that we needed a dedicated reporter covering the use of artificial intelligence in drug R&D. Since then, our senior correspondent Andrew Dunn...
View ArticleAkeso raises $250M; SalioGen’s layoffs
Plus, news about Nicox, Soleus and Molecular Templates: Akeso Biopharma’s $250M placement: The Hong Kong-based company, which is developing a closely watched bispecific antibody with Summit...
View ArticleJasper shares rally as chronic hives drug scores in small, early trial
Jasper Therapeutics’ anti-c-KIT antibody has shown promise in a Phase 1b/2a test in people with certain irritable skin conditions, sending its shares rising on Monday. Fourteen out of 15 participants...
View ArticlePfizer details results from failed Phase 3 trial of Duchenne muscular...
The full results from Pfizer’s pivotal study of its Duchenne muscular dystrophy gene therapy show patients saw no significant functional benefit one year after receiving the therapy despite the...
View ArticleClik here to view.
GSK touts data from two late-stage trials with long-acting drug in chronic...
GSK announced another batch of positive data from its respiratory program with the investigational drug depemokimab, this time in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). Both...
View ArticleTPG and Blackstone working on bid to buy eye care company Bausch + Lomb — report
Private equity firms TPG and Blackstone are working on a potential deal to buy Brent Saunders-led eye care company Bausch + Lomb, the Financial Times reports. Citing “people familiar with the matter,”...
View ArticleEli Lilly reveals £279M investment in the UK through new government deal
Eli Lilly plans to invest £279 million ($364 million) in the UK as part of a new government partnership in which the drugmaker will bring its Gateway Labs overseas for the first time. The...
View ArticleNovartis used a PRV to speed Kisqali's latest indication, FDA says
Novartis used one of its priority review vouchers (PRV) to speed the September approval of Kisqali in early breast cancer, the FDA said Monday. The FDA did not disclose where this PRV came to Novartis...
View ArticleNovo Nordisk files 18 lawsuits against GLP-1 compounders in 44 days
Novo Nordisk filed suit against another semaglutide compounder on Friday, bringing its total number of cases to 50. Both Novo Nordisk and Eli Lilly have launched legal campaigns against medical spas,...
View ArticleClik here to view.
Forbion raises €2.1B for two new biotech funds after series of company exits
Dutch biotech investor Forbion has raised two new funds to put into biotech companies, just 18 months after its last major raise and following a series of successful exits in its portfolio. The new...
View ArticleBiotech tools company Nuclera raises $75M for protein manufacturing tech
Protein production company Nuclera has raised a $75 million Series C to continue to bring its manufacturing platform to market next January after a soft launch in May. “This is a perfect time to start...
View ArticleClik here to view.
Seraxis gets green light for stem cell-derived therapy for diabetes, aiming...
Stem cell biologist William Rust has been quietly working on a cure for diabetes for more than a decade. Later this year, surgeons will implant his company’s pancreatic organoids in people with type 1...
View ArticleTolerance Bio emerges from stealth with $17.2M to advance therapies developed...
Tolerance Bio has launched with an oversubscribed $17.2 million seed round and a goal to develop therapies for immune-mediated diseases, from cancer to transplant rejection, using the thymus. The...
View ArticlePfizer partners with molecular glue startup Triana Biomedicines in $49M...
Pfizer is deepening its investment in protein degraders through a new partnership with Triana Biomedicines, a startup working in the trendy field of molecular glues. The companies will work on multiple...
View ArticleClik here to view.
Walgreens plans to close 1,200 pharmacies
Walgreens is closing 1,200 stores, or 14% of its locations, as it fights to turn around its business. The retail pharmacy chain will be closing the stores over the next three years, the company said in...
View ArticleMeiraGTx's stock rises on small Parkinson's gene therapy dataset
MeiraGTx unveiled results from a small dataset for its Parkinson’s disease gene therapy on Tuesday morning, causing its shares $MGTX to jump by as much as 24%. In what the company called a “bridging...
View ArticleCycle makes another offer for Vanda; Ocean Biomedical, Molecure ink new deal
Plus, news about Gilead Sciences and Yuhan: Vanda gets second unsolicited offer: Cycle Group Holdings again submitted a proposal to buy Vanda for $8 per share in cash. Vanda, which is currently trading...
View ArticleJ&J trims pipeline, including two mid-stage neuroscience studies
Johnson & Johnson cut a handful of trials across its portfolio in the third quarter, including a Phase 2 study of a touted neuroscience treatment. Missing in the company’s updated pipeline list is...
View Article